This is a table of type proper and their frequencies. Use it to search & browse the list to learn more about your study carrel.
proper | frequency |
---|---|
Wuhan | 4957 |
COVID-19 | 3937 |
SARS | 3867 |
China | 3813 |
CoV-2 | 2278 |
el | 1548 |
January | 1154 |
Hubei | 966 |
los | 892 |
Coronavirus | 789 |
CoV | 766 |
PCR | 713 |
Health | 686 |
February | 681 |
con | 679 |
para | 606 |
Table | 551 |
Fig | 544 |
del | 539 |
MERS | 523 |
un | 507 |
CT | 425 |
pacientes | 415 |
las | 411 |
March | 395 |
una | 394 |
Province | 382 |
en | 369 |
Disease | 368 |
Novel | 357 |
ACE2 | 348 |
mcr-9 | 324 |
December | 315 |
Hospital | 314 |
RNA | 285 |
Se | 282 |
por | 279 |
como | 278 |
National | 245 |
CC | 241 |
K. | 239 |
C | 238 |
CI | 225 |
medRxiv | 224 |
World | 217 |
EHV | 216 |
es | 214 |
RT | 214 |
Chinese | 212 |
UK | 211 |
BY | 208 |
ICU | 205 |
Shanghai | 203 |
uso | 202 |
Organization | 200 |
United | 199 |
East | 199 |
PJP | 198 |
LF | 198 |
Commission | 197 |
Beijing | 197 |
Clinical | 196 |
ND | 196 |
NC | 196 |
PJ | 190 |
La | 190 |
recomienda | 189 |
Middle | 185 |
ARDS | 185 |
mg | 182 |
New | 172 |
HCV | 172 |
Europe | 172 |
States | 171 |
CR | 171 |
Wang | 171 |
B. | 169 |
Control | 166 |
Pneumonia | 165 |
City | 163 |
T | 162 |
PRV | 162 |
Italy | 161 |
University | 160 |
Jan | 157 |
US | 156 |
su | 155 |
S | 154 |
• | 154 |
sha | 151 |
Li | 151 |
ventilación | 147 |
B | 144 |
puede | 143 |
S1 | 143 |
Feb | 143 |
April | 142 |
L | 138 |
Huanan | 137 |
Guangdong | 136 |
136 | |
People | 135 |
colistin | 135 |
Shenzhen | 135 |
Figure | 134 |
Prevention | 134 |
Chen | 130 |
Zhang | 127 |
ser | 126 |
paciente | 126 |
Public | 126 |
Leishmania | 126 |
DOI | 126 |
Japan | 124 |
WHO | 123 |
Zhejiang | 123 |
Korea | 122 |
Spain | 121 |
Republic | 119 |
CDC | 119 |
A | 119 |
Science | 118 |
J | 118 |
USA | 117 |
CRKP | 117 |
meta | 116 |
AMCI | 115 |
PPE | 114 |
diagnóstico | 113 |
M | 113 |
enfermedad | 112 |
Respiratory | 112 |
tratamiento | 111 |
UCI | 111 |
IgM | 111 |
lo | 110 |
riesgo | 109 |
estudios | 109 |
IgG | 108 |
Syndrome | 108 |
Transmission | 107 |
mortalidad | 106 |
estudio | 105 |
debe | 105 |
Medical | 105 |
Spring | 104 |
El | 104 |
más | 103 |
Klebsiella | 103 |
IQR | 102 |
SEIR | 102 |
CoVs | 101 |
Pneumocystis | 100 |
Market | 100 |
Liu | 100 |
International | 100 |
Hong | 100 |
Lassa | 99 |
Center | 99 |
Baidu | 99 |
South | 98 |
Festival | 98 |
E. | 98 |
manejo | 97 |
se | 96 |
Huang | 96 |
Henan | 95 |
días | 93 |
LDH | 93 |
Wu | 92 |
Guangzhou | 92 |
Analysis | 92 |
Kong | 90 |
Medicine | 89 |
Care | 89 |
Journal | 88 |
SDRA | 87 |
D | 87 |
mecánica | 86 |
Supplementary | 86 |
S2 | 86 |
Seafood | 85 |
Ebola | 85 |
sospecha | 83 |
Society | 82 |
Cov-2 | 82 |
IL-6 | 81 |
Germany | 81 |
HIV | 81 |
Hunan | 81 |
entre | 81 |
Patients | 81 |
SPD | 81 |
mcr | 81 |
Treatment | 80 |
R | 80 |
PM | 80 |
England | 80 |
Fang | 78 |
Committee | 78 |
Group | 78 |
casos | 78 |
han | 77 |
Data | 77 |
Los | 77 |
Year | 76 |
AI | 76 |
sobre | 75 |
May | 75 |
Association | 75 |
L. | 74 |
Emergency | 74 |
mayor | 74 |
pulmonar | 73 |
intubación | 73 |
Nigeria | 73 |
Infection | 73 |
CFR | 73 |
preprint | 73 |
jirovecii | 72 |
alta | 72 |
London | 72 |
pueden | 71 |
HCWs | 71 |
esta | 71 |
ritonavir | 71 |
cuidados | 70 |
E | 70 |
respiratoria | 69 |
grupo | 69 |
Yang | 69 |
Institute | 69 |
Daegu | 69 |
remdesivir | 68 |
Remdesivir | 68 |
Lancet | 67 |
Report | 67 |
lymphopenia | 67 |
fue | 66 |
N | 66 |
Boltzmann | 66 |
presión | 65 |
personal | 65 |
Research | 65 |
RBD | 65 |
Epidemiology | 65 |
Asia | 65 |
Covid-19 | 64 |
Team | 64 |
R0 | 64 |
U | 64 |
día | 64 |
nan | 63 |
Lombardy | 63 |
June | 63 |
Jiang | 63 |
Enterobacterales | 63 |
DAA | 63 |
CFU | 63 |
October | 62 |
RAS | 62 |
evidencia | 61 |
Singapore | 61 |
Model | 61 |
Foundation | 61 |
Characteristics | 61 |
BAL | 61 |
Study | 60 |
HCQ | 60 |
Molecular | 60 |
PM2.5 | 60 |
II | 60 |
Virus | 60 |
este | 60 |
infección | 60 |
lopinavir | 60 |
tiempo | 60 |
Tokyo | 59 |
September | 59 |
F | 59 |
Pandemic | 58 |
Infectious | 58 |
CRP | 58 |
America | 58 |
PR | 57 |
clínico | 57 |
kg | 57 |
salud | 57 |
≤ | 55 |
horas | 55 |
clínica | 55 |
York | 55 |
TA | 55 |
HC | 55 |
CMV | 55 |
soporte | 54 |
menor | 54 |
Nowcasting | 54 |
NIPH | 54 |
H1N1 | 54 |
Human | 53 |
RaTG13 | 53 |
IC | 52 |
First | 52 |
Early | 52 |
síntomas | 51 |
cols | 51 |
bajo | 51 |
N95 | 51 |
Mainland | 51 |
alto | 50 |
Appendix | 50 |
College | 50 |
Las | 50 |
SPSS | 50 |
cuenta | 50 |
fueron | 50 |
protección | 50 |
si | 50 |
pero | 49 |
State | 49 |
Yu | 48 |
Technology | 48 |
Review | 48 |
ECMO | 48 |
Case | 48 |
TMPRSS2 | 47 |
Global | 47 |
Management | 47 |
atención | 47 |
realizar | 47 |
dosis | 47 |
Diseases | 46 |
Emergence | 46 |
Influenza | 46 |
Municipal | 46 |
NHS | 46 |
Qiagen | 46 |
TNF | 46 |
Viral | 46 |
ZJ01 | 46 |
Zhou | 46 |
contra | 46 |
deben | 46 |
hasta | 46 |
inicio | 46 |
nivel | 46 |
respiratorio | 46 |
son | 46 |
Epidemic | 45 |
MDR | 45 |
clínicos | 45 |
EHV4 | 45 |
Development | 45 |
Response | 45 |
Outbreak | 45 |
compromiso | 45 |
SMX | 45 |
VL | 45 |
oxigenación | 45 |
±10 | 45 |
Toronto | 45 |
Thailand | 44 |
AKI | 44 |
Med | 44 |
Taiwan | 44 |
aguda | 44 |
intensivos | 44 |
oxígeno | 44 |
pandemia | 44 |
− | 44 |
SIR | 43 |
Centre | 43 |
Paris | 43 |
Q | 43 |
Chongqing | 43 |
Union | 43 |
mejoría | 43 |
niveles | 43 |
severa | 43 |
críticos | 43 |
Xu | 42 |
Africa | 42 |
Detection | 42 |
En | 42 |
Risk | 42 |
July | 42 |
cual | 42 |
número | 42 |
otros | 42 |
vía | 42 |
−1 | 42 |
® | 41 |
todos | 41 |
terapia | 41 |
der | 41 |
SAS | 41 |
Jiangsu | 41 |
Impact | 41 |
France | 41 |
Central | 41 |
Hu-1 | 40 |
DM | 40 |
PH | 40 |
resultados | 40 |
Tang | 40 |
seguridad | 39 |
pronóstico | 39 |
ingreso | 39 |
ST | 39 |
Investigation | 39 |
DNA | 39 |
COVID | 39 |
PIBA | 38 |
Natural | 38 |
IV | 38 |
J. | 38 |
KRSFIEDLLFNKV | 38 |
recursos | 38 |
china | 38 |
dos | 38 |
severo | 38 |
Panel | 37 |
Jan. | 37 |
Joint | 37 |
estrategia | 37 |
IFN | 37 |
Dr. | 37 |
Wei | 37 |
S3 | 37 |
utilizar | 37 |
Wholesale | 37 |
convaleciente | 37 |
decisiones | 37 |
doi | 37 |
falla | 37 |
recibieron | 37 |
Montenegro | 36 |
EPP | 36 |
HSV | 36 |
G.F.G. | 36 |
HCU | 36 |
EHV1 | 36 |
Diagnosis | 36 |
AST | 36 |
TMP | 36 |
OXA-48 | 36 |
NDM-1 | 36 |
Trust | 36 |
covid-19 | 36 |
realización | 36 |
donde | 36 |
d3 | 36 |
durante | 36 |
baja | 36 |
tipo | 36 |
Zhu | 36 |
VIM-1 | 36 |
Lunar | 35 |
ACE-2 | 35 |
Candida | 35 |
Changsha | 35 |
Dynamics | 35 |
Hebei | 35 |
Hydroxychloroquine | 35 |
I | 35 |
European | 35 |
RR | 35 |
flujo | 35 |
Rapid | 35 |
manera | 35 |
hipoxemia | 35 |
sido | 35 |
sugiere | 35 |
crítico | 35 |
System | 35 |
Y | 34 |
C. | 34 |
CD4 | 34 |
ELISA | 34 |
HCoV | 34 |
Ministry | 34 |
Sciences | 34 |
34 | |
desde | 34 |
Zhao | 34 |
cuales | 34 |
equipo | 34 |
medidas | 34 |
menos | 34 |
posición | 34 |
sera | 34 |
Estimation | 33 |
Por | 33 |
Intensive | 33 |
Treat | 33 |
Cox | 33 |
COV-2 | 33 |
Social | 33 |
ROC | 33 |
doc_id | 33 |
tiene | 33 |
vida | 33 |
estos | 33 |
considerar | 33 |
diferentes | 33 |
control | 33 |
R. | 32 |
(= | 32 |
Anhui | 32 |
Arabia | 32 |
FDA | 32 |
Fisher | 32 |
Furin | 32 |
M. | 32 |
Poisson | 32 |
Princess | 32 |
Project | 32 |
GGO | 32 |
Shaanxi | 32 |
recomendaciones | 32 |
TCZ | 32 |
wuhan | 32 |
severidad | 32 |
sanitaire | 32 |
reducción | 32 |
Methods | 32 |
necesario | 32 |
condiciones | 32 |
West | 32 |
Tianjin | 32 |
criterios | 32 |
Denmark | 31 |
PEEP | 31 |
Meta | 31 |
Incubation | 31 |
Distress | 31 |
Discovery | 31 |
Chunyun | 31 |
De | 31 |
Centers | 31 |
Carlo | 31 |
Bat | 31 |
PHE | 31 |
Assessment | 31 |
Time | 31 |
Si | 31 |
sin | 31 |
Use | 31 |
γ | 31 |
ya | 31 |
utilización | 31 |
traslado | 31 |
_ | 31 |
luego | 31 |
efectos | 31 |
disponibilidad | 31 |
cuando | 31 |
lesión | 31 |
OC43 | 30 |
8) | 30 |
Abbott | 30 |
Chengdu | 30 |
Dose | 30 |
Ethics | 30 |
III | 30 |
Jiangxi | 30 |
LIWC | 30 |
Monte | 30 |
November | 30 |
SI | 30 |
Patient | 30 |
Qinghai | 30 |
Saudi | 30 |
TL | 30 |
Trial | 30 |
Zhongnan | 30 |
así | 30 |
recomendación | 30 |
α | 30 |
μg | 30 |
X | 30 |
Network | 29 |
Sichuan | 29 |
Romania | 29 |
Guo | 29 |
Hospitalized | 29 |
CoV. | 29 |
G2 | 29 |
G | 29 |
American | 29 |
Administration | 29 |
V5 | 29 |
V4 | 29 |
Inc. | 29 |
aerosoles | 29 |
hospitalaria | 29 |
complicaciones | 29 |
respuesta | 29 |
procedimiento | 29 |
mit | 29 |
infecciones | 29 |
síndrome | 29 |
hepatitis | 29 |
evaluar | 29 |
estándar | 29 |
consentimiento | 29 |
¼ | 29 |
General | 28 |
Protein | 28 |
Log | 28 |
Iran | 28 |
Information | 28 |
District | 28 |
Escherichia | 28 |
Epidemiological | 28 |
Critical | 28 |
Academy | 28 |
Spike | 28 |
Slovenia | 28 |
Lopinavir | 28 |
Th17 | 28 |
decisión | 28 |
Tongji | 28 |
tanto | 28 |
solo | 28 |
plasma | 28 |
disminución | 28 |
sea | 28 |
cada | 28 |
aérea | 28 |
algunos | 28 |
Western | 28 |
Una | 28 |
G1-G3 | 27 |
India | 27 |
IS903 | 27 |
Hospitals | 27 |
HR | 27 |
HLF | 27 |
H7N9 | 27 |
H3 | 27 |
Guidelines | 27 |
Bartha | 27 |
FUNDAMENTO | 27 |
FCS | 27 |
Diamond | 27 |
Department | 27 |
Council | 27 |
Coronavírus | 27 |
Angiotensin | 27 |
ALT | 27 |
LRT | 27 |
K61 | 27 |
asociada | 27 |
Lu | 27 |
WBC | 27 |
tet | 27 |
sputa | 27 |
neumonía | 27 |
Mar | 27 |
https://doi.org/10 | 27 |
ensayos | 27 |
clínicas | 27 |
Y.N.W. | 27 |
mid | 27 |
Travel | 27 |
Serbia | 27 |
Romsdal | 27 |
Pr | 27 |
PT | 27 |
PCV13 | 27 |
NLIA | 27 |
Møre | 27 |
Cochrane | 26 |
H1 | 26 |
GAD-7 | 26 |
Factors | 26 |
Es | 26 |
Corona | 26 |
COVID‐19 | 26 |
Children | 26 |
Cheng | 26 |
Pearson | 26 |
CDCP | 26 |
CD8 | 26 |
PaO2 | 26 |
Chest | 26 |
S. | 26 |
evitar | 26 |
Shi | 26 |
también | 26 |
sus | 26 |
revisión | 26 |
medicamentos | 26 |
volumen | 26 |
disminuir | 26 |
análisis | 26 |
antes | 26 |
Xiao | 26 |
Statistical | 26 |
NCBI | 25 |
AP | 25 |
Belgium | 25 |
Effect | 25 |
Eq | 25 |
Evaluation | 25 |
Guangxi | 25 |
HSCT | 25 |
Ill | 25 |
Kingdom | 25 |
Ltd. | 25 |
Yao | 25 |
tener | 25 |
coronavirus | 25 |
ct | 25 |
general | 25 |
i | 25 |
información | 25 |
médico | 25 |
según | 25 |
teniendo | 25 |
trabajo | 25 |
β | 25 |
aumento | 25 |
Lung | 24 |
K | 24 |
River | 24 |
Patienten | 24 |
Imperial | 24 |
Jin | 24 |
Acute | 24 |
IGIV | 24 |
Healthcare | 24 |
HKU1 | 24 |
Coronaviruses | 24 |
CSF | 24 |
< | 24 |
Reviews | 24 |
Provincial | 24 |
Shandong | 24 |
efecto | 24 |
Viruses | 24 |
tomar | 24 |
servicios | 24 |
series | 24 |
momento | 24 |
intensivo | 24 |
parte | 24 |
cordon | 24 |
comité | 24 |
apoyo | 24 |
acuerdo | 24 |
Yan | 24 |
Xiaogan | 24 |
F1 | 23 |
Systematic | 23 |
Real | 23 |
Nanjing | 23 |
Lin | 23 |
H13 | 23 |
Feng | 23 |
Air | 23 |
Editor | 23 |
Delhi | 23 |
DTW | 23 |
DCCA | 23 |
Chloroquine | 23 |
Canada | 23 |
Vietnam | 23 |
Taxonomy | 23 |
adversos | 23 |
Weibull | 23 |
renal | 23 |
× | 23 |
von | 23 |
viral | 23 |
Wenzhou | 23 |
uno | 23 |
través | 23 |
veces | 23 |
nd | 23 |
médica | 23 |
informado | 23 |
importante | 23 |
eventos | 23 |
beneficio | 23 |
X4 | 23 |
Fuerte | 22 |
Program | 22 |
PHQ-9 | 22 |
North | 22 |
Migration | 22 |
Juan | 22 |
Heart | 22 |
H. | 22 |
H | 22 |
Ritonavir | 22 |
Fu | 22 |
Field | 22 |
Feb. | 22 |
CK | 22 |
Betacoronavirus | 22 |
Australia | 22 |
Associated | 22 |
AAI | 22 |
RECOMENDACIÓN | 22 |
st | 22 |
Seroprevalence | 22 |
estrategias | 22 |
tienen | 22 |
significativa | 22 |
sensibilidad | 22 |
presencia | 22 |
muestras | 22 |
hospitalizados | 22 |
está | 22 |
Structure | 22 |
elevación | 22 |
crítica | 22 |
asociado | 22 |
aire | 22 |
Zengdu | 22 |
X3 | 22 |
Wickramasinghe | 22 |
debido | 22 |
EM | 21 |
PubMed | 21 |
Plasma | 21 |
Perboyre | 21 |
Outcomes | 21 |
Huanggang | 21 |
HCID | 21 |
Fujian | 21 |
Chan | 21 |
ECDC | 21 |
Database | 21 |
DIC | 21 |
Cases | 21 |
CVRP | 21 |
CA | 21 |
Antibody | 21 |
V | 21 |
Un | 21 |
SpO2 | 21 |
Zhong | 21 |
muestra | 21 |
adultos | 21 |
tratados | 21 |
toma | 21 |
siguientes | 21 |
requiere | 21 |
objetivo | 21 |
necesidad | 21 |
multicentre | 21 |
reanimación | 21 |
medición | 21 |
fuera | 21 |
establecer | 21 |
escala | 21 |
críticamente | 21 |
carga | 21 |
anticuerpos | 21 |
invasiva | 21 |
ML | 20 |
Geneva | 20 |
Hu | 20 |
Huoshenshan | 20 |
LSTM | 20 |
SD | 20 |
NCP | 20 |
Para | 20 |
SEIRD | 20 |
Effectiveness | 20 |
Expert | 20 |
Biotech | 20 |
Drug | 20 |
Community | 20 |
CoV2 | 20 |
Clet | 20 |
Carlos | 20 |
CVD | 20 |
CRRT | 20 |
COPD | 20 |
Application | 20 |
Teaching | 20 |
Scientific | 20 |
Chi | 20 |
Washington | 20 |
marzo | 20 |
agudo | 20 |
siendo | 20 |
rutinaria | 20 |
retrospectivo | 20 |
residuos | 20 |
punto | 20 |
tasa | 20 |
prueba | 20 |
presenta | 20 |
mejor | 20 |
sedación | 20 |
kb | 20 |
city | 20 |
analysis | 20 |
gestión | 20 |
calidad | 20 |
ante | 20 |
einer | 20 |
estado | 20 |
factores | 20 |
frecuencia | 20 |
Ref | 19 |
Emerging | 19 |
Mann | 19 |
Latin | 19 |
Kawasaki | 19 |
Heilongjiang | 19 |
H38 | 19 |
Government | 19 |
G1 | 19 |
Cardiac | 19 |
Deng | 19 |
D. | 19 |
Convalescent | 19 |
Cancer | 19 |
CPC | 19 |
AUC | 19 |
AQI | 19 |
Tocilizumab | 19 |
Studies | 19 |
Coronaviridae | 19 |
Whitney | 19 |
dificultad | 19 |
Yuan | 19 |
rutina | 19 |
methotrexate | 19 |
incluyendo | 19 |
grupos | 19 |
evaluaron | 19 |
enfermo | 19 |
eine | 19 |
evolución | 19 |
deterioro | 19 |
dentro | 19 |
curso | 19 |
contexto | 19 |
committee | 19 |
camas | 19 |
azithromycin | 19 |
asociación | 19 |
desenlaces | 19 |
Ji'nan | 18 |
Liang | 18 |
Leishenshan | 18 |
KCDC | 18 |
IBM | 18 |
Int | 18 |
Initiative | 18 |
IS4 | 18 |
Hull | 18 |
Lymphopenia | 18 |
Luminex | 18 |
Nature | 18 |
M-9 | 18 |
MCL | 18 |
MCR-1 | 18 |
MEE | 18 |
MMO | 18 |
Ma | 18 |
NGS | 18 |
NS5A | 18 |
Herpes | 18 |
Norwegian | 18 |
Novo | 18 |
Herpesviridae | 18 |
Enterobacteriaceae | 18 |
Hangzhou | 18 |
Guidance | 18 |
PIB | 18 |
Applied | 18 |
Biosystems | 18 |
CL | 18 |
COV | 18 |
CRE | 18 |
CTX | 18 |
CerTest | 18 |
Clin | 18 |
Consensus | 18 |
Dear | 18 |
Dis | 18 |
EHV-1 | 18 |
Earth | 18 |
F.L. | 18 |
FMT | 18 |
FiO2 | 18 |
G1-treatment | 18 |
G3 | 18 |
GCA_900513855.1 | 18 |
GenBank | 18 |
One | 18 |
PM2 | 18 |
PJIR | 18 |
pMRVIM0813 | 18 |
enfermos | 18 |
final | 18 |
frente | 18 |
función | 18 |
hallazgos | 18 |
hospitalización | 18 |
hydroxychloroquine | 18 |
manifestaciones | 18 |
mcr-8 | 18 |
otras | 18 |
perfusión | 18 |
duración | 18 |
phylogroup | 18 |
presentaron | 18 |
protocolo | 18 |
protocolos | 18 |
ptxA | 18 |
retiro | 18 |
significativamente | 18 |
sistemática | 18 |
tocilizumab | 18 |
unidades | 18 |
elementos | 18 |
metalloprotein | 18 |
disease | 18 |
ST23 | 18 |
cytomegalovirus | 18 |
Poland | 18 |
Poller | 18 |
Progenie | 18 |
Qiu | 18 |
RealCycler | 18 |
RealTime | 18 |
Receptor | 18 |
SHV-11 | 18 |
SOF | 18 |
Peng | 18 |
Salmonella | 18 |
Yangtze | 18 |
Situation | 18 |
cambios | 18 |
adecuado | 18 |
Zaragoza | 18 |
cupin | 18 |
Vero | 18 |
Universitario | 18 |
Sun | 18 |
Gao | 17 |
P<0.001 | 17 |
OD | 17 |
Mental | 17 |
MCMC | 17 |
Laboratory | 17 |
LPV | 17 |
Pulmonary | 17 |
Infections | 17 |
Infected | 17 |
Guan | 17 |
Cryo | 17 |
GWR | 17 |
Fangcang | 17 |
English | 17 |
David | 17 |
Cronbach | 17 |
Creative | 17 |
Commons | 17 |
COVID-2019 | 17 |
Based | 17 |
Adults | 17 |
Therapy | 17 |
Service | 17 |
Cao | 17 |
VTE | 17 |
mediante | 17 |
Xie | 17 |
σ | 17 |
términos | 17 |
social | 17 |
≥ | 17 |
sistema | 17 |
requieren | 17 |
reportaron | 17 |
procesos | 17 |
proceso | 17 |
seguimiento | 17 |
kcal | 17 |
edad | 17 |
humano | 17 |
aún | 17 |
central | 17 |
después | 17 |
Zheng | 17 |
esto | 17 |
evaluación | 17 |
extubación | 17 |
fase | 17 |
NCIP | 16 |
Huazhong | 16 |
Index | 16 |
Jingzhou | 16 |
Microbiology | 16 |
Mission | 16 |
News | 16 |
NO2 | 16 |
Gyeongbuk | 16 |
Phase | 16 |
SARS-2 | 16 |
Section | 16 |
Han | 16 |
Blood | 16 |
Genome | 16 |
GISAID | 16 |
Epidemiologic | 16 |
Environ | 16 |
Education | 16 |
Director | 16 |
DBIL | 16 |
Cohen | 16 |
Cluster | 16 |
CRB-65 | 16 |
CIS | 16 |
TCM | 16 |
Azithromycin | 16 |
ARB | 16 |
Stage | 16 |
Sarbecovirus | 16 |
U.S. | 16 |
implementación | 16 |
Unit | 16 |
± | 16 |
valoración | 16 |
unidad | 16 |
trabajadores | 16 |
siempre | 16 |
riesgos | 16 |
reducir | 16 |
prono | 16 |
probabilidad | 16 |
ningún | 16 |
muy | 16 |
intervenciones | 16 |
pruebas | 16 |
ensayo | 16 |
comparado | 16 |
enfermedades | 16 |
Ying | 16 |
Zhengzhou | 16 |
adecuada | 16 |
bronchoalveolar | 16 |
capacidad | 16 |
Wuchang | 16 |
complejidad | 16 |
contaminación | 16 |
datos | 16 |
daño | 16 |
disponible | 16 |
Party | 15 |
MuLBSTA | 15 |
NHC | 15 |
NIV | 15 |
Northern | 15 |
OR | 15 |
ORF1ab | 15 |
Staff | 15 |
Quality | 15 |
MD | 15 |
Statistics | 15 |
Suizhou | 15 |
Summary | 15 |
VMNI | 15 |
Markov | 15 |
Area | 15 |
Interventions | 15 |
ID-19 | 15 |
Genomic | 15 |
Gabriel | 15 |
Features | 15 |
Esto | 15 |
Environmental | 15 |
E6 | 15 |
Delta | 15 |
Dec | 15 |
Contact | 15 |
Cell | 15 |
CO | 15 |
CD3 | 15 |
Tian | 15 |
Support | 15 |
Yunnan | 15 |
herramienta | 15 |
Zeng | 15 |
zu | 15 |
valores | 15 |
traqueostomía | 15 |
tiempos | 15 |
suficiente | 15 |
situaciones | 15 |
recurso | 15 |
realizaron | 15 |
rd | 15 |
personas | 15 |
monitoreo | 15 |
mmHg | 15 |
ij | 15 |
rendimiento | 15 |
hacer | 15 |
des | 15 |
grave | 15 |
alteraciones | 15 |
aplicación | 15 |
auris | 15 |
cardiovascular | 15 |
cardiovasculares | 15 |
bolsa | 15 |
emitir | 15 |
emodin | 15 |
entrenamiento | 15 |
estancia | 15 |
expertos | 15 |
genera | 15 |
NLR | 14 |
Pro | 14 |
NP | 14 |
Northeast | 14 |
Norway | 14 |
Number | 14 |
Period | 14 |
Population | 14 |
Potential | 14 |
Tool | 14 |
RdRp | 14 |
Res | 14 |
Severe | 14 |
Systems | 14 |
TM | 14 |
Tabla | 14 |
Vaccine | 14 |
Load | 14 |
Microsoft | 14 |
Algorithm | 14 |
Liaoning | 14 |
Daily | 14 |
-3 | 14 |
ALB | 14 |
Xianning | 14 |
Animal | 14 |
Attribution | 14 |
Br | 14 |
DD | 14 |
Diary | 14 |
Level | 14 |
Estos | 14 |
Fan | 14 |
Figs | 14 |
Findings | 14 |
Immune | 14 |
Initial | 14 |
LBS | 14 |
Working | 14 |
Shanxi | 14 |
Yin | 14 |
intensivista | 14 |
ivermectin | 14 |
leve | 14 |
mental | 14 |
metas | 14 |
mostró | 14 |
nutrición | 14 |
posterior | 14 |
temprana | 14 |
todo | 14 |
tratamientos | 14 |
ventilatorio | 14 |
vivo | 14 |
werden | 14 |
áreas | 14 |
útil | 14 |
Yong | 14 |
∼ | 14 |
interleukin-6 | 14 |
prevención | 14 |
insuficiencia | 14 |
dl | 14 |
asociados | 14 |
aumentar | 14 |
inmunoglobulina | 14 |
biomarcadores | 14 |
cardiaca | 14 |
condición | 14 |
contagio | 14 |
controles | 14 |
caso | 14 |
equipos | 14 |
inicial | 14 |
están | 14 |
exposición | 14 |
enfermería | 14 |
ha | 14 |
hospital | 14 |
Ningbo | 13 |
Qi | 13 |
Safety | 13 |
Qing | 13 |
PSQI | 13 |
Pathogenicity | 13 |
PCT | 13 |
Occupational | 13 |
Search | 13 |
School | 13 |
Xue | 13 |
Spread | 13 |
Times | 13 |
UEL | 13 |
Ventilation | 13 |
Version | 13 |
Xi'an | 13 |
Y. | 13 |
Young | 13 |
Z | 13 |
NL63 | 13 |
Newcastle | 13 |
August | 13 |
Modelling | 13 |
Jean | 13 |
ant | 13 |
ADE | 13 |
Ang | 13 |
Army | 13 |
BMI | 13 |
Baltimore | 13 |
Baricitinib | 13 |
COVID- | 13 |
California | 13 |
Critically | 13 |
Design | 13 |
Elsevier | 13 |
Esta | 13 |
Finland | 13 |
Gansu | 13 |
ICTV | 13 |
IES | 13 |
IL | 13 |
Importation | 13 |
anakinra | 13 |
CQ | 13 |
aunque | 13 |
protein | 13 |
otro | 13 |
paro | 13 |
participantes | 13 |
posibilidad | 13 |
presentan | 13 |
primera | 13 |
primeras | 13 |
profesionales | 13 |
protectora | 13 |
respirador | 13 |
nos | 13 |
rápida | 13 |
sanitario | 13 |
saturación | 13 |
terapéutico | 13 |
ti | 13 |
tórax | 13 |
vez | 13 |
μmol | 13 |
cuanto | 13 |
novo | 13 |
respecto | 13 |
moderado | 13 |
específicos | 13 |
cánula | 13 |
mayores | 13 |
demostrado | 13 |
descrito | 13 |
directa | 13 |
disfunción | 13 |
escalas | 13 |
escenarios | 13 |
específico | 13 |
ello | 13 |
esté | 13 |
existe | 13 |
hay | 13 |
incluidos | 13 |
incluye | 13 |
investigación | 13 |
limitaciones | 13 |
estar | 13 |
mascarilla | 13 |
mayo | 13 |
Life | 12 |
Modeling | 12 |
P. | 12 |
NY | 12 |
NPIs | 12 |
Mountain | 12 |
Measures | 12 |
Mobility | 12 |
Meng | 12 |
Media | 12 |
Lv | 12 |
PICU | 12 |
PHEIC | 12 |
W. | 12 |
Prof. | 12 |
S4 | 12 |
Sci | 12 |
Sweden | 12 |
Síndrome | 12 |
TB | 12 |
TGMH | 12 |
Tao | 12 |
Tencent | 12 |
WS | 12 |
Wen | 12 |
Liao | 12 |
Liberation | 12 |
Berlin | 12 |
Language | 12 |
Concern | 12 |
A. | 12 |
African | 12 |
Al | 12 |
Anxiety | 12 |
BD | 12 |
X1 | 12 |
CCMU | 12 |
Cardiovascular | 12 |
Chicago | 12 |
CoVZXC21 | 12 |
Colombia | 12 |
Communist | 12 |
DPP4 | 12 |
Kang | 12 |
Diagnostics | 12 |
DosePM2.5 | 12 |
Epidemia | 12 |
Extended | 12 |
Ezhou | 12 |
Fast | 12 |
G. | 12 |
HR1 | 12 |
Hopkins | 12 |
I(2 | 12 |
IH | 12 |
Identification | 12 |
Wenliang | 12 |
Spearman | 12 |
Xi | 12 |
pulmonares | 12 |
marcadores | 12 |
médicos | 12 |
múltiples | 12 |
negativa | 12 |
negativos | 12 |
ni | 12 |
orotraqueal | 12 |
oseltamivir | 12 |
población | 12 |
primeros | 12 |
procedimientos | 12 |
progresión | 12 |
qué | 12 |
j.jinf.2020.02.019 | 12 |
relación | 12 |
resolución | 12 |
sich | 12 |
signos | 12 |
solución | 12 |
supervivencia | 12 |
tasas | 12 |
tracto | 12 |
troponina | 12 |
técnicas | 12 |
| 12 |
Xiang | 12 |
líquidos | 12 |
realiza | 12 |
institucional | 12 |
cohorte | 12 |
Xinmiao | 12 |
iniciar | 12 |
Ye | 12 |
Yun | 12 |
Zika | 12 |
antiepidemic | 12 |
años | 12 |
bei | 12 |
beneficios | 12 |
capacitación | 12 |
catéter | 12 |
choque | 12 |
basado | 12 |
col | 12 |
fecha | 12 |
inflamación | 12 |
https://doi.org/10.1101/2020.03.04.20026005 | 12 |
hace | 12 |
gravedad | 12 |
forma | 12 |
fármacos | 12 |
documento | 12 |
diferencias | 12 |
detección | 12 |
definir | 12 |
combinación | 12 |
Practice | 11 |
NTD | 11 |
Positive | 11 |
PTSS | 11 |
Origin | 11 |
Open | 11 |
Normal | 11 |
Lockdown | 11 |
NEWS-2 | 11 |
Min | 11 |
Mid | 11 |
Lymr | 11 |
Kaplan | 11 |
Leung | 11 |
Preliminary | 11 |
Prediction | 11 |
Steele | 11 |
Prism | 11 |
Shincheonji | 11 |
Jinyintan | 11 |
TX | 11 |
T. | 11 |
Strogatz | 11 |
Springer | 11 |
Shuang | 11 |
Services | 11 |
Python | 11 |
Sepsis | 11 |
Score | 11 |
Resource | 11 |
Relative | 11 |
Region | 11 |
Qian | 11 |
Johns | 11 |
Bio | 11 |
Italia | 11 |
Church | 11 |
FLRPHE | 11 |
Este | 11 |
Environment | 11 |
Dynamic | 11 |
Comprehensive | 11 |
CoV-1 | 11 |
CNS | 11 |
Inspection | 11 |
British | 11 |
Bian | 11 |
Arbidol | 11 |
Albert | 11 |
ACE | 11 |
V3 | 11 |
Fifth | 11 |
GMT | 11 |
Gong | 11 |
Governance | 11 |
Grad | 11 |
Guillain | 11 |
Guizhou | 11 |
HBPM | 11 |
HUST | 11 |
Hainan | 11 |
Host | 11 |
Hui | 11 |
ID | 11 |
IL-10 | 11 |
ISI | 11 |
Illumina | 11 |
Inhibitors | 11 |
Thermo | 11 |
-8 | 11 |
Watts | 11 |
papel | 11 |
prona | 11 |
predecir | 11 |
posible | 11 |
pesar | 11 |
permite | 11 |
patologías | 11 |
nomogram | 11 |
quienes | 11 |
multicéntrico | 11 |
ml | 11 |
miocárdica | 11 |
mejora | 11 |
manos | 11 |
línea | 11 |
práctica | 11 |
refractaria | 11 |
identificar | 11 |
tenían | 11 |
X2 | 11 |
ventilador | 11 |
técnica | 11 |
tuvieron | 11 |
tres | 11 |
transfusión | 11 |
temprano | 11 |
relacionadas | 11 |
t. | 11 |
sofosbuvir | 11 |
sobrevida | 11 |
será | 11 |
segura | 11 |
respiración | 11 |
lograr | 11 |
puntos | 11 |
https://doi.org/10.1101/2020.03.31.20049387 | 11 |
altas | 11 |
cardiaco | 11 |
bioética | 11 |
author(s | 11 |
aumenta | 11 |
arritmias | 11 |
alteración | 11 |
admisión | 11 |
citocinas | 11 |
adicional | 11 |
además | 11 |
acceso | 11 |
abril | 11 |
Zhoushan | 11 |
hidroxicloroquina | 11 |
centro | 11 |
anticoagulación | 11 |
coronaviruses | 11 |
egreso | 11 |
health | 11 |
fiebre | 11 |
esteroides | 11 |
específica | 11 |
eliminación | 11 |
elevados | 11 |
hemodinámica | 11 |
east | 11 |
dispositivos | 11 |
disponibles | 11 |
disnea | 11 |
demostró | 11 |
deberá | 11 |
LDA | 10 |
Mongolia | 10 |
Mini | 10 |
Meier | 10 |
MAbs | 10 |
Long | 10 |
Legionella | 10 |
Labour | 10 |
Jiangxia | 10 |
Kim | 10 |
Jun | 10 |
Mycobacterium | 10 |
Jianghan | 10 |
Interim | 10 |
Imai | 10 |
Imaging | 10 |
Mr. | 10 |
Traditional | 10 |
Ningxia | 10 |
PAR | 10 |
Hilden | 10 |
Tohoku | 10 |
Th | 10 |
Statement | 10 |
Song | 10 |
Shen | 10 |
SEMCR | 10 |
SCLIWC | 10 |
Recommendations | 10 |
RP | 10 |
QIAamp | 10 |
Provinces | 10 |
Problem | 10 |
Pan | 10 |
10 | |
IFR | 10 |
A1 | 10 |
HCoV-229E | 10 |
Con | 10 |
Clínico | 10 |
Chain | 10 |
CRISPR | 10 |
COVID19 | 10 |
CAM | 10 |
Barr | 10 |
Asymptomatic | 10 |
Anti | 10 |
Age | 10 |
Abstract | 10 |
AZ | 10 |
APEC | 10 |
ACEI | 10 |
WH | 10 |
2D | 10 |
Computing | 10 |
Crisis | 10 |
Gram | 10 |
Cross | 10 |
Gene | 10 |
GI | 10 |
Finalmente | 10 |
Failure | 10 |
FGMH | 10 |
Epstein | 10 |
Enterobacter | 10 |
Eliseo | 10 |
Efficacy | 10 |
ESR | 10 |
EBV | 10 |
Dong | 10 |
DFE | 10 |
DALY | 10 |
Culture | 10 |
UI | 10 |
Action | 10 |
Walsh | 10 |
monitoria | 10 |
posibles | 10 |
podrían | 10 |
peso | 10 |
parámetros | 10 |
paliativos | 10 |
necesarios | 10 |
national | 10 |
modelos | 10 |
hubo | 10 |
marco | 10 |
mRNA | 10 |
lugar | 10 |
intervención | 10 |
intensidad | 10 |
incluir | 10 |
impacto | 10 |
positivity | 10 |
posteriores | 10 |
primer | 10 |
propone | 10 |
Waste | 10 |
Δ | 10 |
óptimo | 10 |
éticos | 10 |
área | 10 |
van | 10 |
todas | 10 |
sulfamethoxazole | 10 |
situación | 10 |
sistemas | 10 |
secuelas | 10 |
rt | 10 |
reportado | 10 |
quien | 10 |
puntaje | 10 |
identificación | 10 |
recuperación | 10 |
hospitales | 10 |
comparación | 10 |
características | 10 |
cadáver | 10 |
asoció | 10 |
aparición | 10 |
alveolar | 10 |
ajustar | 10 |
aislamiento | 10 |
Z. | 10 |
Yi | 10 |
Xin | 10 |
Wilcoxon | 10 |
10 | |
Wavelet | 10 |
hacia | 10 |
Wave | 10 |
chemoprophylaxis | 10 |
adecuación | 10 |
componentes | 10 |
determinar | 10 |
guías | 10 |
generales | 10 |
confirmado | 10 |
experiencia | 10 |
encontraron | 10 |
ellos | 10 |
diferencia | 10 |
efectividad | 10 |
desinfectante | 10 |
das | 10 |
confirmados | 10 |
células | 10 |
cuadro | 10 |
continuo | 10 |
considera | 10 |
Kebbi | 9 |
MALDI | 9 |
MCR | 9 |
MB | 9 |
Loughborough | 9 |
Luzatti | 9 |
Jing | 9 |
Key | 9 |
Leismania | 9 |
MGIT | 9 |
MCR-9 | 9 |
Material | 9 |
MIC | 9 |
MN908947.3 | 9 |
Maidenhead | 9 |
Manchester | 9 |
Maritati | 9 |
Maryland | 9 |
Mechanism | 9 |
Medicina | 9 |
Jia | 9 |
Mengmeng | 9 |
Metagenomic | 9 |
Jilin | 9 |
Hill | 9 |
Jensen | 9 |
Hua | 9 |
Mycobacteria | 9 |
HRCT | 9 |
Haberling | 9 |
Hafnia | 9 |
Harbin | 9 |
Hb | 9 |
Hercules | 9 |
HiSeq | 9 |
Holshue | 9 |
Hortega | 9 |
IAME | 9 |
Jandrić | 9 |
IC90 | 9 |
INSERM | 9 |
IPD | 9 |
IS30 | 9 |
Indicator | 9 |
Irrua | 9 |
Isolation | 9 |
Italian | 9 |
JCYJ20170303155012371 | 9 |
JR18/0 | 9 |
Microbiol | 9 |
Rad | 9 |
Médecins | 9 |
Randomized | 9 |
Psoriasis | 9 |
PwMS | 9 |
QIA | 9 |
QT | 9 |
RGNOSIS | 9 |
RIT | 9 |
RITM | 9 |
RVP | 9 |
HCU- | 9 |
Radiology | 9 |
Reactive | 9 |
Procalcitonin | 9 |
Renmin | 9 |
Reporting | 9 |
Researchers | 9 |
Resistance | 9 |
Rhinolophus | 9 |
Rodés | 9 |
Routing | 9 |
Río | 9 |
SARI | 9 |
SDS | 9 |
Promotion | 9 |
Preparedness | 9 |
N. | 9 |
PBRT | 9 |
NDM | 9 |
NS5B | 9 |
Neutrophil | 9 |
OMB | 9 |
OXA-10 | 9 |
Ondo | 9 |
Oxford | 9 |
Oxoid | 9 |
PAFI | 9 |
PAH | 9 |
PN:52906 | 9 |
Polymyxin | 9 |
PP | 9 |
Palermo | 9 |
Paolo | 9 |
Pediatric | 9 |
Plan | 9 |
Plasmid | 9 |
Platelia | 9 |
PneumoVir | 9 |
Pneumocysis | 9 |
Politécnico | 9 |
HFNC | 9 |
EHV8 | 9 |
H5N6 | 9 |
Brunet | 9 |
Background | 9 |
Barré | 9 |
Bayesian | 9 |
Becton | 9 |
Belfast | 9 |
Biomerieux | 9 |
Bordetella | 9 |
Boyan | 9 |
Brain | 9 |
Brazil | 9 |
CJAD | 9 |
B.L.Z. | 9 |
CLART | 9 |
CM18/00221 | 9 |
CMY-16 | 9 |
CXR | 9 |
Cai | 9 |
Career | 9 |
Castle | 9 |
Catholics | 9 |
Chang | 9 |
Chowdhury | 9 |
BCYE | 9 |
Authority | 9 |
Guideline | 9 |
Ag | 9 |
SOD | 9 |
0ed3c6a5559cd73307184f51fc53ccc76da559bc | 9 |
1/3200 | 9 |
3D | 9 |
3a | 9 |
3rd | 9 |
500/125 | 9 |
A(H7N4 | 9 |
ABI | 9 |
AIDS | 9 |
Alliance | 9 |
Author | 9 |
Alphaherpesvirinae | 9 |
Amin | 9 |
Amirthalingam | 9 |
Amphotericin | 9 |
Antibiotic | 9 |
Antimicrobial | 9 |
Approach | 9 |
Aspergillus | 9 |
Aujeszky | 9 |
Austin | 9 |
Chun | 9 |
Colonization | 9 |
Comparative | 9 |
G4 | 9 |
F. | 9 |
Fatigue | 9 |
Fe | 9 |
Fellowship | 9 |
Filmarray | 9 |
Fischer | 9 |
Five | 9 |
Flu | 9 |
Frontières | 9 |
G.P.Z. | 9 |
GCA_900501685.1 | 9 |
Contigs | 9 |
GENE | 9 |
GIS | 9 |
GLE | 9 |
GRZ | 9 |
Genomica | 9 |
Giaccone | 9 |
Giménez | 9 |
Grocott | 9 |
Growth | 9 |
Guided | 9 |
Excellent | 9 |
Event | 9 |
Estela | 9 |
Equine | 9 |
Coproduction | 9 |
Corporation | 9 |
Coslada | 9 |
Cytospin | 9 |
DAAs | 9 |
Definition | 9 |
Delphi | 9 |
Diagnostic | 9 |
Dickinson | 9 |
Drigalski | 9 |
ECIL | 9 |
EHV1-EHV9 | 9 |
EHV5 | 9 |
EHVs | 9 |
ELB | 9 |
EU | 9 |
EZ-1 | 9 |
Economic | 9 |
Edo | 9 |
Entry | 9 |
Enzyme | 9 |
SEAIR | 9 |
MIU | 9 |
SZSM201512030 | 9 |
mejorar | 9 |
les | 9 |
liberación | 9 |
log | 9 |
lymphocytopenia | 9 |
mcr-1 | 9 |
mcr-1.1 | 9 |
mcr-3 | 9 |
mcr-7.1 | 9 |
medicina | 9 |
medida | 9 |
microcopy | 9 |
lactato | 9 |
modelo | 9 |
monitorización | 9 |
moral | 9 |
mostraron | 9 |
nacional | 9 |
nervioso | 9 |
ng | 9 |
observacional | 9 |
ofrecer | 9 |
oxytoca | 9 |
ledipasvir | 9 |
laborato | 9 |
pCTXM9_020038 | 9 |
huésped | 9 |
gasto | 9 |
geno2pheno | 9 |
global | 9 |
guyanensis | 9 |
herpesviruses | 9 |
histopathological | 9 |
historia | 9 |
hormaechei | 9 |
http://www.progenie-molecular.com/PJIR-U-IN.pdf | 9 |
http://www.stats.gov.cn/tjsj/zxfb/ | 9 |
hygromycin | 9 |
key | 9 |
immunoprophylaxis | 9 |
implementar | 9 |
incidencia | 9 |
incluso | 9 |
incremento | 9 |
infantum | 9 |
infectados | 9 |
inferior | 9 |
iniciales | 9 |
j.jinf.2020.01.019 | 9 |
p.o | 9 |
pME-1a | 9 |
formación | 9 |
±60 | 9 |
tomografía | 9 |
total | 9 |
trimethoprim | 9 |
trombosis | 9 |
uploads/2019/02 | 9 |
ward | 9 |
wpontent | 9 |
www.geno2pheno.org | 9 |
www.gov.uk/government/publications/wuhan-novelcoronavirus-infection-prevention-and-control/wuhan-novel-coronavirus-wncov-infection-prevention-and-control-guidance | 9 |
±3 | 9 |
±70 | 9 |
terapéutica | 9 |
ésta | 9 |
índices | 9 |
último | 9 |
λ(t | 9 |
−2 | 9 |
−92 | 9 |
∼28 | 9 |
∼8.7 | 9 |
≥400 | 9 |
Sabouraud | 9 |
tet(X | 9 |
tenía | 9 |
panamensis | 9 |
publicación | 9 |
phenicols | 9 |
plan | 9 |
pneumococci | 9 |
pneumocystis | 9 |
pneumoniae | 9 |
positivos | 9 |
predictores | 9 |
presentación | 9 |
previamente | 9 |
primero | 9 |
qSOFA | 9 |
temperatura | 9 |
quasipneumoniae | 9 |
razonable | 9 |
resistencia | 9 |
ries | 9 |
sintomatología | 9 |
sp1.pdf | 9 |
sugieren | 9 |
sul2 | 9 |
t.d.s | 9 |
telesalud | 9 |
galactomannan | 9 |
paralvei | 9 |
fold | 9 |
Vehicle | 9 |
Thrombocytopenia | 9 |
Transport | 9 |
Tube)/Lowenstein | 9 |
Tyne | 9 |
Typhimurium | 9 |
UMR-1137 | 9 |
Université | 9 |
VEL | 9 |
VIASURE | 9 |
Varicellovirus | 9 |
WGS | 9 |
TEM-1 | 9 |
Welders | 9 |
Wellcome | 9 |
Wh | 9 |
Wong | 9 |
XF | 9 |
Xiangyang | 9 |
Xinjiang | 9 |
Xiong | 9 |
Y.F.H. | 9 |
Yichang | 9 |
TOF | 9 |
Symphony | 9 |
ZC45 | 9 |
SoC | 9 |
San | 9 |
fenotipos | 9 |
Sanatorium | 9 |
Sanger | 9 |
Sanming | 9 |
Sans | 9 |
Scale | 9 |
Semiquantitative | 9 |
Serotype | 9 |
Shaw | 9 |
Sophia | 9 |
Survey | 9 |
Sothern | 9 |
Sport | 9 |
Sputa | 9 |
Sputasol | 9 |
Stress | 9 |
Su | 9 |
Subclinical | 9 |
Suidae | 9 |
SuperPolymyxin | 9 |
Superpolymyxin | 9 |
Z/18 | 9 |
TMP/800 | 9 |
Zamfara | 9 |
diffuse | 9 |
content/10.1101/2020.02.12.20022327v1 | 9 |
continua | 9 |
crystalloid | 9 |
cuidado | 9 |
d2 | 9 |
dados | 9 |
definida | 9 |
den | 9 |
department | 9 |
dexametasona | 9 |
difícil | 9 |
compararon | 9 |
dímero | 9 |
eHealth | 9 |
eficacia | 9 |
endophthalmitis | 9 |
enterobacter | 9 |
epidemia | 9 |
especificidad | 9 |
espontánea | 9 |
estén | 9 |
familia | 9 |
consenso | 9 |
desinfección | 9 |
amazonensis | 9 |
assembly | 9 |
comorbilidades | 9 |
Zuqin | 9 |
ab | 9 |
acerca | 9 |
administración | 9 |
alerta | 9 |
aph(4)-Ia | 9 |
aquellos | 9 |
asistencial | 9 |
✩ | 9 |
Zhongyan | 9 |
ausencia | 9 |
blaVIM-4-and | 9 |
bloqueo | 9 |
calcofluor | 9 |
cambio | 9 |
carbapenem | 9 |
chronic | 9 |
citoquinas | 9 |
claro | 9 |
Zhongyu | 9 |
Protocol | 8 |
Personal | 8 |
Position | 8 |
Post | 8 |
Protection | 8 |
Lee | 8 |
Regulations | 8 |
Ren | 8 |
Richard | 8 |
Pangolin | 8 |
Régis | 8 |
Pattern | 8 |
Ling | 8 |
Pacific | 8 |
PaO | 8 |
PRISMA | 8 |
ORF8 | 8 |
Mortality | 8 |
Mar. | 8 |
Manual | 8 |
Manejo | 8 |
MWC | 8 |
MEDLINE | 8 |
Lian | 8 |
SR | 8 |
SIS | 8 |
Yue | 8 |
Scopus | 8 |
Tibet | 8 |
LZ | 8 |
association | 8 |
antimaláricos | 8 |
azitromicina | 8 |
YX | 8 |
Workers | 8 |
WAIC | 8 |
Virology | 8 |
VOC | 8 |
Total | 8 |
Tong | 8 |
Theory | 8 |
Second | 8 |
Testing | 8 |
Test | 8 |
Task | 8 |
Tan | 8 |
Tab | 8 |
Switzerland | 8 |
Surveillance | 8 |
Surto | 8 |
Subgroup | 8 |
Stability | 8 |
Semiformal | 8 |
Lai | 8 |
Airborne | 8 |
LAMP | 8 |
Bank | 8 |
Ct | 8 |
Corticosteroid | 8 |
Como | 8 |
Coherence | 8 |
Co. | 8 |
Cities | 8 |
COVID-19-related | 8 |
Bureau | 8 |
Breakthrough | 8 |
Blue | 8 |
Biotechnology | 8 |
BMJ | 8 |
Depression | 8 |
BCG | 8 |
Authorization | 8 |
Armonk | 8 |
ArcGIS | 8 |
Alphacoronavirus | 8 |
Airport | 8 |
Affairs | 8 |
Adult | 8 |
ACV | 8 |
ACO | 8 |
base | 8 |
Da | 8 |
Disaster | 8 |
Jingmen | 8 |
Handbook | 8 |
Jie | 8 |
JL | 8 |
JAMA | 8 |
Investigating | 8 |
Inner | 8 |
Inference | 8 |
Individual | 8 |
IL-1 | 8 |
ICUs | 8 |
Huangshi | 8 |
Headquarters | 8 |
8 | |
Dr | 8 |
Gautam | 8 |
GZ02 | 8 |
GS-5734 | 8 |
GD | 8 |
François | 8 |
Force | 8 |
FFP2 | 8 |
Excel | 8 |
Evolution | 8 |
Engineering | 8 |
Embase | 8 |
bajos | 8 |
incluyeron | 8 |
bioseguridad | 8 |
primario | 8 |
replicación | 8 |
reciente | 8 |
realizarse | 8 |
quirúrgica | 8 |
puedan | 8 |
publicado | 8 |
publicaciones | 8 |
proteína | 8 |
pronación | 8 |
profunda | 8 |
procalcitonina | 8 |
prevenir | 8 |
rápidamente | 8 |
preoxigenación | 8 |
positivo | 8 |
patología | 8 |
optimizar | 8 |
obtener | 8 |
objetivos | 8 |
nítrico | 8 |
neurológicas | 8 |
negativas | 8 |
necesaria | 8 |
mínimo | 8 |
respiradores | 8 |
s(+∞ | 8 |
muerte | 8 |
variabilidad | 8 |
broncoscopia | 8 |
ε | 8 |
óxido | 8 |
ética | 8 |
| | 8 |
xxx | 8 |
wird | 8 |
vital | 8 |
virales | 8 |
ventilados | 8 |
vasculares | 8 |
utilizados | 8 |
sangre | 8 |
transmisión | 8 |
tormenta | 8 |
tolerancia | 8 |
sólo | 8 |
superior | 8 |
sobrevivientes | 8 |
sobrecarga | 8 |
siguiendo | 8 |
significativo | 8 |
serie | 8 |
sean | 8 |
muestran | 8 |
segunda | 8 |
modalidades | 8 |
disease-2019 | 8 |
evitando | 8 |
estrés | 8 |
estas | 8 |
específicas | 8 |
especiales | 8 |
espacio | 8 |
enero | 8 |
encefalitis | 8 |
efectiva | 8 |
dolor | 8 |
disposición | 8 |
desarrollo | 8 |
falta | 8 |
derechos | 8 |
demanda | 8 |
dar | 8 |
correlación | 8 |
controlado | 8 |
contar | 8 |
colaboradores | 8 |
cerebro | 8 |
cerebral | 8 |
middle | 8 |
capilar | 8 |
factor | 8 |
describieron | 8 |
frecuente | 8 |
institucionales | 8 |
medio | 8 |
medicamento | 8 |
frecuentes | 8 |
mecanismos | 8 |
limpieza | 8 |
le | 8 |
laboratorio | 8 |
isquémico | 8 |
intravenosa | 8 |
interferón | 8 |
intensivistas | 8 |
kw | 8 |
hemodinámico | 8 |
ingresados | 8 |
inflamatorios | 8 |
indirecta | 8 |
igual | 8 |
hyperimmune | 8 |
garantizar | 8 |
https://doi.org/10.1101/2020.03.03.20030353 | 8 |
https://doi.org/10.1101/2020.01.27.20018986 | 8 |
group | 8 |
grado | 8 |
Publisher | 7 |
Rev | 7 |
Prof | 7 |
Pittsburgh | 7 |
Pulmonar | 7 |
PRC | 7 |
Rothe | 7 |
Respir | 7 |
Qianxi | 7 |
Que | 7 |
RTV | 7 |
Responses | 7 |
Retrospective | 7 |
PDB | 7 |
POCUS | 7 |
Nanshan | 7 |
P | 7 |
Organ | 7 |
Observational | 7 |
OS | 7 |
ORF1a | 7 |
Nutrition | 7 |
Note | 7 |
Nishiura | 7 |
Nipah | 7 |
NT | 7 |
NPI | 7 |
NK | 7 |
Russia | 7 |
Mobile | 7 |
Rt | 7 |
anosmia | 7 |
S5 | 7 |
YW | 7 |
Mechanical | 7 |
ataque | 7 |
aspectos | 7 |
artículos | 7 |
antivirales | 7 |
anterior | 7 |
altos | 7 |
alternativa | 7 |
agua | 7 |
ageusia | 7 |
agentes | 7 |
adecuadamente | 7 |
actividades | 7 |
X. | 7 |
SEIQR | 7 |
Wikipedia | 7 |
W | 7 |
Unknown | 7 |
Ultrasound | 7 |
Transportation | 7 |
Theorem | 7 |
Tables | 7 |
TH | 7 |
Stroke | 7 |
Strategies | 7 |
Shu | 7 |
Sheng | 7 |
Seoul | 7 |
Mechanisms | 7 |
Bin | 7 |
Matrix | 7 |
Capital | 7 |
ECG | 7 |
Dímero | 7 |
Dysregulation | 7 |
Disease-2019 | 7 |